These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

702 related articles for article (PubMed ID: 21709064)

  • 1. Calcium Upregulation by Percutaneous Administration of Gene Therapy in Cardiac Disease (CUPID): a phase 2 trial of intracoronary gene therapy of sarcoplasmic reticulum Ca2+-ATPase in patients with advanced heart failure.
    Jessup M; Greenberg B; Mancini D; Cappola T; Pauly DF; Jaski B; Yaroshinsky A; Zsebo KM; Dittrich H; Hajjar RJ;
    Circulation; 2011 Jul; 124(3):304-13. PubMed ID: 21709064
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Design of a phase 2b trial of intracoronary administration of AAV1/SERCA2a in patients with advanced heart failure: the CUPID 2 trial (calcium up-regulation by percutaneous administration of gene therapy in cardiac disease phase 2b).
    Greenberg B; Yaroshinsky A; Zsebo KM; Butler J; Felker GM; Voors AA; Rudy JJ; Wagner K; Hajjar RJ
    JACC Heart Fail; 2014 Feb; 2(1):84-92. PubMed ID: 24622121
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Calcium upregulation by percutaneous administration of gene therapy in patients with cardiac disease (CUPID 2): a randomised, multinational, double-blind, placebo-controlled, phase 2b trial.
    Greenberg B; Butler J; Felker GM; Ponikowski P; Voors AA; Desai AS; Barnard D; Bouchard A; Jaski B; Lyon AR; Pogoda JM; Rudy JJ; Zsebo KM
    Lancet; 2016 Mar; 387(10024):1178-86. PubMed ID: 26803443
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Calcium upregulation by percutaneous administration of gene therapy in cardiac disease (CUPID Trial), a first-in-human phase 1/2 clinical trial.
    Jaski BE; Jessup ML; Mancini DM; Cappola TP; Pauly DF; Greenberg B; Borow K; Dittrich H; Zsebo KM; Hajjar RJ;
    J Card Fail; 2009 Apr; 15(3):171-81. PubMed ID: 19327618
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term effects of AAV1/SERCA2a gene transfer in patients with severe heart failure: analysis of recurrent cardiovascular events and mortality.
    Zsebo K; Yaroshinsky A; Rudy JJ; Wagner K; Greenberg B; Jessup M; Hajjar RJ
    Circ Res; 2014 Jan; 114(1):101-8. PubMed ID: 24065463
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intracoronary Sarcoplasmic Reticulum Calcium-ATPase Gene Therapy in Advanced Heart Failure Patients with reduced Ejection Fraction: A Prospective Cohort Study.
    Zhang J; Hu G; Yang S
    Clinics (Sao Paulo); 2020; 75():e1530. PubMed ID: 32187281
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of intracoronary administration of AAV1/SERCA2a on ventricular remodelling in patients with advanced systolic heart failure: results from the AGENT-HF randomized phase 2 trial.
    Hulot JS; Salem JE; Redheuil A; Collet JP; Varnous S; Jourdain P; Logeart D; Gandjbakhch E; Bernard C; Hatem SN; Isnard R; Cluzel P; Le Feuvre C; Leprince P; Hammoudi N; Lemoine FM; Klatzmann D; Vicaut E; Komajda M; Montalescot G; Lompré AM; Hajjar RJ;
    Eur J Heart Fail; 2017 Nov; 19(11):1534-1541. PubMed ID: 28393439
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gene therapy for heart failure.
    Greenberg B
    J Cardiol; 2015 Sep; 66(3):195-200. PubMed ID: 25818479
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Changes in ventricular remodelling and clinical status during the year following a single administration of stromal cell-derived factor-1 non-viral gene therapy in chronic ischaemic heart failure patients: the STOP-HF randomized Phase II trial.
    Chung ES; Miller L; Patel AN; Anderson RD; Mendelsohn FO; Traverse J; Silver KH; Shin J; Ewald G; Farr MJ; Anwaruddin S; Plat F; Fisher SJ; AuWerter AT; Pastore JM; Aras R; Penn MS
    Eur Heart J; 2015 Sep; 36(33):2228-38. PubMed ID: 26056125
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intracoronary Gene Transfer of Adenylyl Cyclase 6 in Patients With Heart Failure: A Randomized Clinical Trial.
    Hammond HK; Penny WF; Traverse JH; Henry TD; Watkins MW; Yancy CW; Sweis RN; Adler ED; Patel AN; Murray DR; Ross RS; Bhargava V; Maisel A; Barnard DD; Lai NC; Dalton ND; Lee ML; Narayan SM; Blanchard DG; Gao MH
    JAMA Cardiol; 2016 May; 1(2):163-71. PubMed ID: 27437887
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Randomized Clinical Trials of Gene Transfer for Heart Failure with Reduced Ejection Fraction.
    Penny WF; Hammond HK
    Hum Gene Ther; 2017 May; 28(5):378-384. PubMed ID: 28322590
    [TBL] [Abstract][Full Text] [Related]  

  • 12. New insights into SERCA2a gene therapy in heart failure: pay attention to the negative effects of B-type natriuretic peptides.
    Zhai Y; Luo Y; Wu P; Li D
    J Med Genet; 2018 May; 55(5):287-296. PubMed ID: 29478009
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MicroRNA therapy for the failing heart.
    Martinez-Fernandez A
    Circ Cardiovasc Genet; 2014 Jun; 7(3):393-4. PubMed ID: 24951666
    [No Abstract]   [Full Text] [Related]  

  • 14. Effect of spironolactone on diastolic function and exercise capacity in patients with heart failure with preserved ejection fraction: the Aldo-DHF randomized controlled trial.
    Edelmann F; Wachter R; Schmidt AG; Kraigher-Krainer E; Colantonio C; Kamke W; Duvinage A; Stahrenberg R; Durstewitz K; Löffler M; Düngen HD; Tschöpe C; Herrmann-Lingen C; Halle M; Hasenfuss G; Gelbrich G; Pieske B;
    JAMA; 2013 Feb; 309(8):781-91. PubMed ID: 23443441
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Design of a Phase 3 trial of intracoronary administration of human adenovirus 5 encoding human adenylyl cyclase type 6 (RT-100) gene transfer in patients with heart failure with reduced left ventricular ejection fraction: The FLOURISH Clinical Trial.
    Penny WF; Henry TD; Watkins MW; Patel AN; Hammond HK
    Am Heart J; 2018 Jul; 201():111-116. PubMed ID: 29763816
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting sarcoplasmic reticulum calcium ATPase by gene therapy.
    Gwathmey JK; Yerevanian A; Hajjar RJ
    Hum Gene Ther; 2013 Nov; 24(11):937-47. PubMed ID: 24164241
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treating anemia in older adults with heart failure with a preserved ejection fraction with epoetin alfa: single-blind randomized clinical trial of safety and efficacy.
    Maurer MS; Teruya S; Chakraborty B; Helmke S; Mancini D
    Circ Heart Fail; 2013 Mar; 6(2):254-63. PubMed ID: 23258574
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of Inorganic Nitrite vs Placebo on Exercise Capacity Among Patients With Heart Failure With Preserved Ejection Fraction: The INDIE-HFpEF Randomized Clinical Trial.
    Borlaug BA; Anstrom KJ; Lewis GD; Shah SJ; Levine JA; Koepp GA; Givertz MM; Felker GM; LeWinter MM; Mann DL; Margulies KB; Smith AL; Tang WHW; Whellan DJ; Chen HH; Davila-Roman VG; McNulty S; Desvigne-Nickens P; Hernandez AF; Braunwald E; Redfield MM;
    JAMA; 2018 Nov; 320(17):1764-1773. PubMed ID: 30398602
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Benefit of SERCA2a gene transfer to vascular endothelial and smooth muscle cells: a new aspect in therapy of cardiovascular diseases.
    Lipskaia L; Hadri L; Lopez JJ; Hajjar RJ; Bobe R
    Curr Vasc Pharmacol; 2013 Jul; 11(4):465-79. PubMed ID: 23905641
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of Liraglutide on Clinical Stability Among Patients With Advanced Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial.
    Margulies KB; Hernandez AF; Redfield MM; Givertz MM; Oliveira GH; Cole R; Mann DL; Whellan DJ; Kiernan MS; Felker GM; McNulty SE; Anstrom KJ; Shah MR; Braunwald E; Cappola TP;
    JAMA; 2016 Aug; 316(5):500-8. PubMed ID: 27483064
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 36.